Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037953 | 0.81 | LMNA (0.44) | TP53LMNAHTT | |
| SCHEMBL8285924 | 0.81 | LMNA (0.44) | TP53LMNAHTT | |
| SCHEMBL14168780 | 0.81 | LMNA (0.44) | TP53LMNAHTT | |
| SCHEMBL15157546 | 0.81 | — | — | |
| SCHEMBL15129327 | 0.80 | TP53 (0.57) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL10396654 | 0.80 | TP53 (0.57) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL14981213 | 0.80 | TP53 (0.57) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL14677340 | 0.79 | TP53 (0.61) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL10483800 | 0.79 | TP53 (0.56) | TP53LMNAHTTIDO1TDO2 | |
| Hydrochloric Acid SCHEMBL4933838 | 0.79 | LMNA (0.43) | TP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-9783493-B2 | Quinone derivative and electrophotographic photosensitive member | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783493-B2 | Quinone derivative and electrophotographic photosensitive member | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20160152557-A1 | QUINONE DERIVATIVE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152557-A1 | QUINONE DERIVATIVE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2337778-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | Absolute Science, INC. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | TREH, BRIX1, GBA1 | TP53 4561/4885LMNA 1689/4885HTT 2968/4885 |
| US-20160152557-A1 | QUINONE DERIVATIVE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER | KEAP1, RAD54L, NQO2 | TP53 2614/4885LMNA 3771/4885HTT 3821/4885 |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | TP53 2232/4885LMNA 1805/4885HTT 1082/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | TP53 4251/4885LMNA 1069/4885HTT 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.